Literature DB >> 1719552

Expression of acidic and basic fibroblast growth factors in the substantia nigra of rat, monkey, and human.

A J Bean1, R Elde, Y H Cao, C Oellig, C Tamminga, M Goldstein, R F Pettersson, T Hökfelt.   

Abstract

The distribution of acidic (aFGF) and basic (bFGF) fibroblast growth factor mRNA and protein were examined in mesencephalon by immunohistochemistry, immunoblot analysis, in situ hybridization histochemistry, and RNA analysis. Coexistence of aFGF or bFGF with tyrosine hydroxylase protein in nigral cells was observed with immunohistochemistry. Both aFGF and bFGF mRNAs were found in the substantia nigra. Unilateral 6-hydroxydopamine lesions of nigrostriatal neurons resulted in a loss of aFGF and tyrosine hydroxylase [L-tyrosine, tetrahydropteridine: oxygen oxidoreductase (3-hydroxylating), EC 1.14.16.2] mRNA-positive neurons on the lesioned side. The distribution of aFGF mRNA in monkey brain was similar to that seen in the rat. RNA and immunoblot analysis confirmed the presence of both aFGF and bFGF mRNAs and proteins in the substantia nigra of rat, monkey, and human.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1719552      PMCID: PMC52903          DOI: 10.1073/pnas.88.22.10237

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Localization of FGF receptor mRNA in the adult rat central nervous system by in situ hybridization.

Authors:  A Wanaka; E M Johnson; J Milbrandt
Journal:  Neuron       Date:  1990-09       Impact factor: 17.173

2.  Nuclear and cytoplasmic localization of different basic fibroblast growth factor species.

Authors:  M Renko; N Quarto; T Morimoto; D B Rifkin
Journal:  J Cell Physiol       Date:  1990-07       Impact factor: 6.384

3.  Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II.

Authors:  B Knusel; P P Michel; J S Schwaber; F Hefti
Journal:  J Neurosci       Date:  1990-02       Impact factor: 6.167

4.  Specific stimulation of in vitro maturation of mesencephalic dopaminergic neurones by striatal membranes.

Authors:  A Prochiantz; M C Daguet; A Herbet; J Glowinski
Journal:  Nature       Date:  1981 Oct 15-21       Impact factor: 49.962

5.  Human acidic fibroblast growth factor overexpressed in insect cells is not secreted into the medium.

Authors:  Y H Cao; R F Pettersson
Journal:  Growth Factors       Date:  1990       Impact factor: 2.511

6.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

Authors:  A J Ekstrand; C D James; W K Cavenee; B Seliger; R F Pettersson; V P Collins
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

7.  BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra.

Authors:  C Hyman; M Hofer; Y A Barde; M Juhasz; G D Yancopoulos; S P Squinto; R M Lindsay
Journal:  Nature       Date:  1991-03-21       Impact factor: 49.962

Review 8.  The changing scene of neurotrophic factors.

Authors:  H Thoenen
Journal:  Trends Neurosci       Date:  1991-05       Impact factor: 13.837

9.  Neuropeptide Y and catecholamine synthesizing enzymes and their mRNAs in rat sympathetic neurons and adrenal glands: studies on expression, synthesis and axonal transport after pharmacological and experimental manipulations using hybridization techniques and radioimmunoassay.

Authors:  M Schalling; A Franco-Cereceda; A Hemsén; A Dagerlind; K Seroogy; H Persson; T Hökfelt; J M Lundberg
Journal:  Neuroscience       Date:  1991       Impact factor: 3.590

10.  Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors.

Authors:  C A Dionne; G Crumley; F Bellot; J M Kaplow; G Searfoss; M Ruta; W H Burgess; M Jaye; J Schlessinger
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

View more
  16 in total

1.  Neurotrophic factors in neurodegenerative disorders: model of Parkinson's disease.

Authors:  J Garcia de Yebenes; J Yebenes; M A Mena
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

2.  New paradigms for collateral vessel growth.

Authors:  W Schaper
Journal:  Basic Res Cardiol       Date:  1993 May-Jun       Impact factor: 17.165

3.  Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication.

Authors:  M Mogi; M Harada; T Kondo; P Riederer; T Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Basic fibroblast growth factor protects against rotenone-induced dopaminergic cell death through activation of extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase pathways.

Authors:  Shih-Ling Hsuan; Heather M Klintworth; Zhengui Xia
Journal:  J Neurosci       Date:  2006-04-26       Impact factor: 6.167

5.  Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism.

Authors:  R Maggio; M Riva; F Vaglini; F Fornai; G Racagni; G U Corsini
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 6.  Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease.

Authors:  G W Ross; H Petrovitch
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

7.  Basic fibroblast growth factor in rat salivary glands.

Authors:  O Amano; Y Yoshitake; K Nishikawa; S Iseki
Journal:  Cell Tissue Res       Date:  1993-09       Impact factor: 5.249

8.  The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway.

Authors:  A Ueki; L Rosén; B Andbjer; U B Finnman; U Altamimi; A M Janson; M Goldstein; L F Agnati; K Fuxe
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

9.  Strain difference in the up-regulation of FGF-2 protein following a neurotoxic lesion of the nigrostriatal pathway.

Authors:  David M Yurek; Anita M Fletcher; Laura E Peters; Wayne A Cass
Journal:  Neurochem Res       Date:  2010-04       Impact factor: 3.996

Review 10.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.